Adage Capital Partners’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Adage Capital Partners’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-158,333	Closed	-$1.8M	–	788
2014 Q4	$1.8M	Hold	158,333	–	–	﹤0.01%	673
2014 Q3	$1.82M	Hold	158,333	–	–	﹤0.01%	675
2014 Q2	$3.08M	Hold	158,333	–	–	0.01%	640
2014 Q1	$2.84M	Hold	158,333	–	–	0.01%	631
2013 Q4	$1.67M	Hold	158,333	–	–	﹤0.01%	644
2013 Q3	$1.96M	Hold	158,333	–	–	0.01%	645
2013 Q2	$1.49M	Buy	+158,333	New	+$2.03M	﹤0.01%	652

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Adage Capital Partners's CASC Position: Q1 2015 in Review

Adage Capital Partners sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2015, closing a stake of 158,333 shares — an estimated $1.8M sold.

Adage Capital Partners first reported a position in CASC in Q2 2013 and held it in 7 quarters. The position peaked at $3.08M in Q2 2014. 90 funds tracked by Wall St. Rank hold CASC as of Q1 2015.

Adage Capital Partners reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
Adage Capital Partners sold 158,333 Cascadian Therapeutics, Inc. shares in Q1 2015, an estimated $1.8M.
Adage Capital Partners first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 7 quarters.
Adage Capital Partners's Cascadian Therapeutics, Inc. position peaked at $3.08M in Q2 2014.
90 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2015.

Based on Adage Capital Partners's 13F filing for Q1 2015, filed 15 May 2015.